Emergent BioSolutions Closes New Loan Facility
Emergent BioSolutions Inc. has taken a significant step in fortifying its financial groundwork by closing a $100 million asset-backed loan facility. This strategic decision, made in late September, amplifies Emergent's liquidity, enabling reinforced support for its multi-year transformation program.
Details of the Loan Facility
The arrangement allows for an asset-based revolving loan facility (ABL) with an aggregate principal amount reaching up to $100 million. This revolving loan commitment is subject to a defined borrowing base which offers Emergent considerable flexibility. Crucially, the loan comes with a fixed maturity date set for September 30, 2029, although early maturity triggers exist based on other significant debts.
Supporting Corporate Growth Plans
With this new funding option, Emergent aims to bolster its operational resilience and align with goals focused on long-term sustainability and growth. As of the end of September, the company recorded a cash balance of approximately $150 million alongside undrawn access to its ABL facility, illustrating robust liquidity management.
Comments from Leadership
Joe Papa, the President and CEO of Emergent, expressed satisfaction with the terms of the new credit facility. He noted, "We are pleased to have successfully closed on our new ABL credit facility with favorable terms and an extended maturity, which is further evidence of Emergent's strengthened balance sheet and financial position." Papa emphasized the importance of this facility for continuing Emergent's strategic objectives and stabilization efforts.
Previous Financial Moves
This credit facility development follows the company's earlier announcement about refinancing its debt through a collaboration with Oak Hill Advisors, securing a term loan potentially reaching $250 million. These financial maneuvers reflect a proactive approach in ensuring Emergent's capacity to navigate the complexities of the health landscape while maintaining operational effectiveness and bolstering investor confidence.
About Emergent BioSolutions
Emergent BioSolutions is dedicated to protecting and enhancing life by preparing for and addressing public health threats. With over 25 years of experience, the company develops and manufactures vaccines and therapeutics aimed at meeting urgent health needs. Furthermore, it provides integrated contract development and manufacturing services tailored for pharmaceutical and biotechnology clients, reinforcing its commitment to public health.
Investor and Media Contacts
For further inquiries, Richard S. Lindahl, the Executive Vice President and CFO, is available at lindahlr@ebsi.com. Assal Hellmer, Vice President of Communications, can be reached at mediarelations@ebsi.com.
Frequently Asked Questions
What is the purpose of the new loan facility?
The new loan facility aims to provide Emergent BioSolutions with the liquidity necessary to support its multi-year transformation plan and operational stability.
When does the loan facility mature?
The fixed maturity date for the loan facility is set for September 30, 2029, with certain provisions for early maturity under specific circumstances.
How will this financial move support Emergent's operations?
The additional funds will allow Emergent to reinforce its financial position, enabling better support for long-term strategic goals and public health initiatives.
Who can I contact for investor relations?
For investor relations inquiries, Richard S. Lindahl is the contact and can be reached via his email at lindahlr@ebsi.com.
What has Emergent done recently in terms of debt management?
Recently, Emergent restructured its debt through a new credit facility agreement with Oak Hill Advisors, securing a potential term loan of up to $250 million.